Janssen Promoted Risperdal Off Label, Jury Hears

Law360, Philadelphia (September 25, 2012, 8:40 PM EDT) -- Ortho-McNeil-Janssen Pharmaceuticals Inc. directed its salespeople to push the antipsychotic drug Risperdal for mood and behavioral disorders in children despite the risk male patients might grow breasts as a side effect, a former regional manager for the company told a jury Tuesday.

Tone Jones, a former sales manager with Janssen, testified in Pennsylvania state court as part of a case brought by Texas teenager Andrew Bentley, who claims off-label use of Risperdal led to his gynecomastia, which is the abnormal development of mammary glands in males....
To view the full article, register now.